

**Investment Brief for
Software Risk Calculator HRT and Cancer**

**NSW
AREA HEALTH
SERVICES**

Office of Commercialisation

For further information under a Confidential Disclosure Agreement, please contact the following OoC team member

***Dr Russell Carrington
Sydney West Area Health Service – Office of Commercialisation
Mob: +61 (0) 425 251 314
Ph: 61 2 9845 6079
e-mail: russell.carrington@officeofcommercialisation.com
Westmead Hospital PO Box 90 Westmead (Sydney) NSW
2145 Australia***

Software Risk Calculator HRT and Cancer

Summary

A software based risk calculator which is able to estimate HRT use and cancer risk has been developed by Prof John Boyages and colleagues at the NSW Breast Cancer Institute, SWAHS. This software enables rapid assessment of the likelihood of a patient's susceptibility to breast cancer.

Market

This technology meets an unmet need in the clinical environment to guide medical professionals in the most appropriate use of HRT.

Benefit

The prediction of the likelihood of an individual developing breast cancer has wide application to all medical professionals dealing with women using HRT.

Investment Brief

- Industry:** Medical Software
- Proposed Business:** Sophisticated software-based calculator able to estimate an individual's breast cancer risk for any woman of any nationality
- Team:**
- Prof John Boyages
NSW Breast Cancer Institute, SWAHS
(02) 9845 8490
johnb@bci.org.au
- Dr Nathan J Coombs
NSW Breast Cancer Institute, SWAHS
(02) 9845 8490
davidr@westgate.wh.usyd.edu.au

Business Description

A software-based risk calculator which is able to estimate HRT use and breast cancer risk. It is intended for use by general practitioners, gynaecologists, breast surgeons and individual women and women's groups. The calculator applies published HRT relative risk data to local breast cancer incidence data to provide an individual's breast cancer risk. This technique and methodology is applicable to any population worldwide allowing calculation of a woman's absolute breast cancer risk and estimating the additional risk for that woman with different formulations and duration of HRT use.

Value Proposition

The calculator would assist many consultations with women who may be concerned regarding their perceived additional breast cancer risk from HRT or family history and enable clinicians to provide individualized care to women. There is currently no other product on the market that is able to predict breast cancer risk to HRT users.

Potential Market Applications of the Technology

Breast cancer is the second leading cause of cancer deaths in women today (after lung cancer) and is the most common cancer among women, excluding non-melanoma skin cancers. According to the World Health Organization, more than 1.2 million people will be diagnosed with breast cancer this year worldwide. The American Cancer Society estimated that in 2005, approximately 211,240 women in the United States would be diagnosed with invasive breast cancer (Stages I-IV). The chance of developing invasive breast cancer during a woman's lifetime is approximately 1 in 7 (13.4%). The calculator is intended for use by general practitioners, gynaecologists, breast surgeons, breast cancer services, and public hospitals.

Competitors

To our knowledge there is no previous invention which uses dotNET technology to display a HRT Calculator based on the life time risk of breast cancer.

Sustainable Advantage

Both inventors have extensive experience in the diagnosis and treatment of breast cancer and hold important positions in the NSW Breast Cancer Institute. They have access to a large pool of patients and there is international interest for the development/testing of the calculator.

Status of Intellectual Property

An Australian provisional patent “Determining the risk of breast cancer for a woman”, # 2005901619, was filed on April 1, 2005 by Sydney West Area Health Service (SWAHS).